‘Real world’ use of non-vitamin K antagonist oral anticoagulants (NOACs): Lessons from the Dresden NOAC Registry

John W. Eikelboom; Jeffrey I. Weitz

doi:10.1160/TH15-02-0158

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2015; 113(06): 1159-1161
DOI: 10.1160/TH15-02-0158

Invited Editorial Focus

Schattauer GmbH

‘Real world’ use of non-vitamin K antagonist oral anticoagulants (NOACs): Lessons from the Dresden NOAC Registry

John W. Eikelboom

¹McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada

,

Jeffrey I. Weitz

¹McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada

References
1 Ruff CT, Giugliano RP, Braunwald E. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955-962.
2 Yeh CH, Gross PL, Weitz JI. Evolving use of new oral anticoagulants for treatment of venous thromboembolism. Blood 2014; 124: 1020-1028.
3 Hankey GJ. Unanswered questions and research priorities to optimise stroke prevention in atrial fi-brillation with the new oral anticoagulants. Thromb Haemost 2014; 111: 808-816.
4 Hylek EM, Ko D, Cove CL. Gaps in translation from trials to practice: non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation. Thromb Haemost 2014; 111: 783-788.
5 De Caterina R, Husted S, Wallentin L. et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013; 110: 1087-1107.
6 Larsen TB, Rasmussen LH, Skjoth F. et al. Efficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 2013; 61: 2264-2273.
7 Sorensen R, Gislason G, Torp-Pedersen C, et al. Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. Br Med J Open 2013; 3.
8 Larsen TB, Gorst-Rasmussen A, Rasmussen LH. et al. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. Am J Med 2014; 127: 650-656.
9 Olesen JB, Sorensen R, Hansen ML. et al. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naive atrial fibrillation patients: Danish nationwide descriptive data 2011–2013. Europace 2015; 17: 187-193.
10 Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med 2013; 368: 1272-1274.
11 Vaughan Sarrazin MS, Jones M. et al. Bleeding rates in Veterans Affairs patients with atrial fibrillation who switch from warfarin to dabigatran. Am J Med 2014; 127: 1179-1185.
12 Hernandez I, Baik SH, Pinera A. et al. Risk of bleeding with dabigatran in atrial fibrillation. J Am Med Assoc Intern Med 2015; 175: 18-24.
13 Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 2015; 131: 157-164.
14 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
15 Beyer-Westendorf J, Gelbricht V, Forster K, et al. Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care--results from the Dresden NOAC registry. Br J Clin Pharmacol 2014; 78: 908-917.
16 Beyer-Westendorf J, Gelbricht V, Forster K, et al. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J 2014; 35: 1888-1896.
17 Beyer-Westendorf J, Forster K, Pannach S, et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood 2014; 124: 955-962.
18 Chin PK, Wright DF, Patterson DM. et al. A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time. Br J Clin Pharmacol 2014; 78: 599-609.
19 Vanassche T, Hirsh J, Eikelboom JW. et al. Organspecific bleeding patterns of anticoagulated patient: lessons from clinical trials. Thromb Haemost 2014; 112: 918-923.
20 Chan NC, Coppens M, Hirsh J. et al. Real-world variability in dabigatran levels in patients with atrial fibrillation. J Thromb Haemost. 2014. Epub ahead of print
21 Camm AJ, Lip GY, De Caterina R. et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-2747.
22 Verma A, Cairns JA, Mitchell LB. et al. 2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. Can J Cardiol 2014; 30: 1114-1130.
23 Beyer-Westendorf J, Ebertz F, Förster K, et al. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost 2015; 113: 1247-1257.